All In Biotech

Drug Trial Radar · NCT03199950

PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel

Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model?

Last checked: Nov 20, 2026Latest source record: Jun 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,366 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,366

Planned (sponsor's estimate)

Start

Jun 23, 2017

Primary completion

Nov 23, 2018

Study completion Nov 23, 2018

Sponsor

Lead sponsor
Zuyderland Medisch CentrumAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The hospital pharmacy at the Zuyderland Medical Centre developed the DElirium MOdel (DEMO) to predict which patients are at risk of developing a delirium in patients aged 60 or older. With this delirium risk prediction model we aim to predict more accurately which patients are at high risk of developing a delirium and want to investigate if these patients can benefit from prophylactic haloperidol.

Conditions

  • Delirium

Interventions

  • HaloperidolDrug

    Haloperidol 2dd1mg (08.00am - 10.00pm)

  • Placebo Oral TabletDrug

    Placebo oral 2dd (08.00am - 10.00pm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurence of deliriumTime frame: Delirium within 5 days postoperative

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zuyderland Medisch Centrum

    Sittard, Limburg, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.